期刊文献+

药代动力学参数估算方法概述 被引量:2

下载PDF
导出
摘要 群体药代动力学(Population Pharmacokinetics,PPK)是将经典的药动学基本原理和统计学模型相结合以分析药物代谢动力学特性中存在的变异性(确定性变异和随机性变异),研究药物体内过程的群体规律、药动学参数的统计分布及其影响因素的一门新兴学科。通过PPK参数,包括群体典型值、固定效应参数、个体间变异、个体内变异定量,考察患者群体中药物浓度的决定因素。自1998年美国食品药品监督管理局(FDA)允许群体分析法在新药Ⅱ、Ⅲ期临床试验中用于特殊生理病理受试对象的药动学评价以来,
出处 《中国医药导报》 CAS 2009年第13期8-10,共3页 China Medical Herald
  • 相关文献

参考文献18

二级参考文献35

  • 1Undre NA, Schafer A. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group Transplantation Proc, 1998, 30(4): 1261.
  • 2David A, Askow L, Lavio F, et al. An open label, concentration ranging trial of FK506 in primary kidney transplantayion. Transplantation, 1996,62:900.
  • 3Undre NA, Stevenson P, Schafer A. Pharmacokinetics of tacrolimus:Clinically relevant aspects. Transplantation Proc, 1999, 31: 21s.
  • 4Ihara H, Shinkuma D, Ichikawa Y, et al. Intra- interindividual variation in the pharmacokinetics of tacrolimuss (FK506) in kidney transplant recipients- importance of trough level as a practical indicate. Int J Urol,1995, 2:151.
  • 5Venkataramanan R, Jain A, Warty VS, et al. Pharmacokinetics of FK506in transplant patients. Transplantation Proc, 1991,23:2736.
  • 6Undre NA, Stevenson P, Schafer A. Pharmacokinetics of tacrolinus:Clinically relevant aspects. Transplantation Proc, 1999, 31: 21s.
  • 7Mekki Q, Phd MD, Lee C, et al. Pharmacokinetics of Tacrolimus(FK506) in kidney transplant patients. Clin Pharamcol Ther, 1993, 54:238.
  • 8Mahalati K, Belitsky P, Kiberd B, et al. Absorption profiling- a novel method for monitoring neoral in kidney transplantation that reduces rejection and nephrotoxicity. Transplantation, 2000,69:s114.
  • 9Reith DM, Hooper WD, Parke J, et al. Population pharmacokinetic modeling of steady state carbamazapine clearance in children, adolescents, and adults[ J]. J pharmacokinet pharmacodynam,2001 ;28: 79- 92.
  • 10Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet, 1995, 29:404-430.

共引文献64

同被引文献21

  • 1王正容,罗丽娅,刘萍,钱文璟.氟康唑对妊娠妇女的生殖毒性研究进展[J].中南药学,2005,3(4):235-237. 被引量:4
  • 2贺福元,罗杰英,邓凯文.中药复方动力学数学模型-总量统计矩法的研究[J].世界科学技术-中医药现代化,2006,8(6):13-18. 被引量:37
  • 3Tiboni GM.Second brachial arch anomalies induced by fluconazole,a his-triazole antifungal agent,in cultured mouse embryos[J].Res Commun Chem Pathol Pharmacol,1993,79(2):381-384.
  • 4Inman W,Pearee G,Wilton L.Safety of fluconazole in the treatment of vaginal candidiasis:a prescription-event monitoring study,with special reference to the outcome of pregnancy[J].Eur J Clin Pharmacol,1994,46(5):115-118.
  • 5Mastroiacovo P,Mazzone T,Eotto LD,et al.Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole[J].Am J Obstet Gynecol,1996,175(6):1645-1650.
  • 6Jick SS.Pregnancy outcomes after maternal exposure to fluconazole[J].Pharmacotherapy,1999,19(2):221-222.
  • 7Henrik TR,Gunnar LN,Charlotte O,et al.Risk of malformations and other outcomes in children exposed to fluconazole in utero[J].British Journal of Clinical Pharmacology,1999,48(2):234.
  • 8Lee BE,Feinberg M,Abraham JJ,et al.Congenital malformations in an infant born to a women treated with fluconazole[J].Pediatr Infect Dis J,1992,11(3):1062-1064.
  • 9Pursley TJ,Blomquist JK,Abraham JJ,et al.Fluconazole-induced congenital anomalies in three infants[J].Clin Infect Dis,1996,22(8):336-340.
  • 10Aleek KA,Bartley DL.Multiple malformation syndrome following fluconazole use in pregnancy:report of an additional patient[J].Am J Med Genet,1997,72(9):253-256.

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部